The TOGETHER Project - Liver

2019-03-19 05:48:23 | BioPortfolio


To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.


The study is a prospective, observational study utilizing peripheral blood assays that will be collected at time points that are considered standard of care at most institutions. 100 participants will be enrolled in study. Participants will have peripheral blood collected at 4 months and 12 months after liver transplant, as well as any for cause time points. Participants will also have liver biopsies collected at these time points. The results from the liver biopsies will be used in correlation with the results from the peripheral blood assays.

Study Design


Liver Transplant Rejection


Liver Transplant


Mayo Clinic
United States




Mayo Clinic

Results (where available)

View Results


Published on BioPortfolio: 2019-03-19T05:48:23-0400

Clinical Trials [6213 Associated Clinical Trials listed on BioPortfolio]

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

People who have liver transplants must take anti-rejection medication (immunosuppression) for the rest of their lives. If they stop, their immune system may reject the transplanted liver....

Medication Adherence in Children Who Had a Liver Transplant

The purpose of this study is to evaluate the use of a novel method to measure adherence to immunosuppressant medications in predicting rejection episodes in children who had a liver transp...

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

This study involves the use of a drug called Thymoglobulin, which is approved in the US to treat kidney transplant rejection and in Canada to treat and prevent kidney transplant rejection....

Liver Transplants in People With HIV Infection

HIV infected people are at increased risk for liver disease and failure, leading to the need for a liver transplant. Many HIV infected people are refused a transplant because it has been ...

Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C

Acute cellular rejection is relatively common after liver transplantation, typically does not affect graft survival, and is not associated with the development of chronic rejection. Acute ...

PubMed Articles [5999 Associated PubMed Articles listed on BioPortfolio]

Protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene polymorphisms in liver transplant donors and impact on acute cellular liver transplant rejection.

The PTPN22 gene encodes the lymphoid protein tyrosine phosphatase involved in regulation the immune response. The single nucleotide polymorphisms (SNPs) rs1217388, rs1310182, rs2476601, and rs2488457 ...

Protocol for histological examination of liver transplant dysfunction.

The protocol for histological examination of liver transplant dysfunction, which is used at the A.I. Burnazyan, Federal Medical and Biophysical Center and has been developed on the basis of the liver ...

Macrosteatotic Allografts and Obese Recipients Have Nearly Equal Negative Impact on Liver Transplant Survival.

Our aim was to evaluate liver transplant outcomes involving donors with high macrosteatosis grafts in the obese modern liver transplant recipient population.

Pre- and Peri-Operative Factors Associated with Chronic Critical Illness in Liver Transplant Recipients.

Chronic critical illness (CCI) is a new and increasing entity that accounts for substantial cost despite its low incidence. We hypothesized that patients with end-stage liver failure undergoing liver ...

Acute Cellular Rejection in hepatitis C recipients Following Liver Transplantation in the Era of Direct Acting Antivirals: Chronological Analysis of UNOS Database.

Interferon (IFN) treatment for liver transplant (LT) recipients with hepatitis C virus (HCV) increases acute cellular rejection (ACR), and worsens graft and patient survival. It is unknown if direct a...

Medical and Biotech [MESH] Definitions

An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)

A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.

Sudden liver failure in the presence of underlying compensated chronic LIVER DISEASE (e.g., LIVER CIRRHOSIS; HEPATITIS; and liver injury and failure) due to a precipitating acute hepatic insult.

More From BioPortfolio on "The TOGETHER Project - Liver"

Quick Search

Relevant Topics

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Searches Linking to this Trial